A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
About the study
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD) patients
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi® treatment according to locally approved label
- Patients who are willing to provide written informed consent prior to study enrollment
EXCLUSION CRITERIA
Exclusion Criteria:
- Patients under 12 years old
- Patients with contraindication according to locally approved label of Jakavi®
- Patients who receive or are going to receive any investigational medicine during the observation period.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Graft-versus-Host Disease
Age
12 - 100
Participants Needed
127
Est. Completion Date
May 13, 2026
Treatment Type
OBSERVATIONAL
Sponsor
Novartis
ClinicalTrials.gov NCT Identifier
NCT05621733
Study Number
CINC424C2415
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?